STOCK TITAN

Medpace (MEDP) director exercises 3,858 options and sells 795 common shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Medpace Holdings, Inc. director Cornelius P. McCarthy III exercised stock options for 3,858 shares of common stock on 2026-08-07 at an exercise price of $84.36 per share. He then reported acquiring the same number of common shares through the exercise and selling 795 shares of common stock at a reported price of $585.071 per share. The exercised option, which covered 3,858 underlying shares, had vested in full on May 13, 2021 and carried an expiration date of May 15, 2027.

Positive

  • None.

Negative

  • None.
Insider McCarthy Cornelius P. III
Role Director
Sold 795 shs ($465K)
Approx. gross sale proceeds $465K
Approx. exercise cost $325K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1 3,858 $0.00 $0.00
Exercise Common Stock 3,858 $84.36 $325K
Sale Common Stock 795 $585.071 $465K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 13,415 shares (Direct)
Footnotes (1)
  1. F1. The option vested in full on May 13, 2021.
Options Exercised 3,858 shares Stock Option (Right to Buy) exercised on 2026-08-07
Option Exercise Price $84.36 per share Exercise price of Stock Option (Right to Buy)
Shares Sold 795 shares Common Stock sale on 2026-08-07
Sale Price $585.071 per share Reported price for 795-share Common Stock sale
Option Expiration May 15, 2027 Expiration date of exercised stock option
Option Vesting Date May 13, 2021 Date option vested in full per footnote
Net Buy/Sell Shares -795 shares transactionSummary netBuySellShares indicating net-sell activity
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy) for 3,858 shares"
Exercise or conversion of derivative security financial
"transaction_code_description states Exercise or conversion of derivative security"
Common Stock financial
"underlying_security_title and security_title reference Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Rule 10b5-1 regulatory
"aff_10b5_one is the Rule 10b5-1 checkbox indicator"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock option did Medpace (MEDP) director Cornelius P. McCarthy III exercise?

Cornelius P. McCarthy III exercised a Stock Option (Right to Buy) covering 3,858 shares of Medpace common stock at an exercise price of $84.36 per share. The option had vested fully on May 13, 2021 and was set to expire on May 15, 2027.

How many Medpace (MEDP) shares did Cornelius P. McCarthy III sell in this Form 4?

He sold 795 shares of Medpace common stock on 2026-08-07 at a reported price of $585.071 per share. This sale followed the exercise of stock options for 3,858 shares the same day, as disclosed in the filing data.

Was the Medpace (MEDP) insider transaction under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox was not marked as true, so the transactions were not affirmed as being made under a Rule 10b5-1 trading plan. No additional trading-plan details appear in the provided footnotes.

What is the exercise price and expiration for the Medpace (MEDP) option exercised?

The exercised stock option had an exercise price of $84.36 per share and an expiration date of May 15, 2027. It related to 3,858 underlying shares of Medpace common stock and was fully vested as of May 13, 2021.

What is the overall share impact of this Medpace (MEDP) Form 4 transaction?

The insider exercised options for 3,858 shares and sold 795 shares of common stock. The transaction summary shows exerciseShares of 3,858 and sellShares of 795, resulting in net-sell activity of 795 shares across buy/sell transactions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCarthy Cornelius P. III

(Last)(First)(Middle)
C/O MEDPACE HOLDINGS, INC.
5375 MEDPACE WAY

(Street)
CINCINNATI OHIO 45227

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026M3,858A$84.3614,210D
Common Stock08/07/2026S795D$585.07113,415D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$84.3608/07/2026M3,858 (1)05/15/2027Common Stock3,858$00D
Explanation of Responses:
1. The option vested in full on May 13, 2021.
Remarks:
/s/ Stephen P. Ewald, Attorney-in-Fact for Cornelius P. McCarthy III08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)